Chinook Therapeutics Inc expected to post a loss of 78 cents a share - Earnings Preview

Chinook Therapeutics

11/08/2021 03:51

* Chinook Therapeutics Inc  KDNY.OQ   KDNY.O  is expected
to show a fall in quarterly revenue when it reports results on
August 11 (estimated). 
* The Seattle, Washington-based company is expected to report 
 a 99.3% decrease in revenue to $41.67 thousand from $5.57
million a year ago, according to the mean estimate from 6
analysts, based on Refinitiv data. 
​* Refinitiv's mean analyst estimate for Chinook Therapeutics
Inc is for a loss of 78 cents per share. For the same quarter
last year, the company reported a loss of $1.05 per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 8 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Chinook
Therapeutics Inc is $31​, about 60.4% above​ its last closing
price of $12.29. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.65       -0.68      -0.88     Missed  -30
 Dec. 31 2020  -0.51       -0.44      -1.24     Missed  -178.7
 Sep. 30 2020  -0.49       -0.45      -0.90     Missed  -97.8​
 Jun. 30 2020  -1.01       -0.95      -1.05     Missed  -10.5
 Mar.          -0.76​      -0.67      -0.45     Beat    33.3​
 31​ 2020​                                              
 Dec. 31 2019  -1.07       -1.05      -1.20     Missed  -13.9​
 Sep. 30 2019  -1.17       -1.16      -1.00     Beat    13.7
 Jun. 30 2019  -1.15       -0.91      -1.15     Missed  -26.1
 This summary was machine generated August 11 at 02:51 GMT.  All
figures in US dollars unless otherwise stated